Going to #ESMO23? We will be there from Oct 20-23. Come to booth 726a and explore the past, present, and potential future treatment options for unresectable hepatocellular carcinoma (uHCC). Plus, you can make an appointment to discuss the latest data. See you soon! https://hubs.ly/Q024bqv90 #ElevatingOutcomes #EveryMeasureMatters #ElevarAtESMO23
Elevar Therapeutics’ Post
More Relevant Posts
-
At #ASCO24, we spoke with Peter R. Galle, MD, PhD, of Universitätsmedizin Mainz on the results of CheckMate-9DW for unresectable hepatocellular carcinoma. Learn how #nivolumab plus #ipilimumab fared against #sorafenib and #lenvatinib as a first-line treatment: https://buff.ly/4c4hO69
To view or add a comment, sign in
-
🩻 Discover our infographic that explains and details the read criteria modified RECIST for Hepatocellular Carcinoma (HCC): https://hubs.li/Q026pWDD0 #medicalimaging #HCC #mRECIST
To view or add a comment, sign in
-
Get the latest perspectives on treatment approaches for unresectable advanced hepatocellular carcinoma. See all regions and reports available and download the sample report: https://lnkd.in/e9VA_Tvm #CancerResearch #GIcancer
Click Here to See All Available Reports!
To view or add a comment, sign in
-
👩🔬 Dr. Falcone is back to discuss the shear-thinning hydrogels used in our latest publication. The publication showcases our innovative hydrogel platform developed to treat Hepatocellular Carcinoma. Find out more about this publication and our other applications of the shear-thinning hydrogels at Terasaki .org #TerasakiInstitute #HepatocellularCarcinoma
To view or add a comment, sign in
-
Be sure to read this #clinicalinvestigation 🔍 #Percutaneous Microwave #Ablation Versus Robot-Assisted Partial Nephrectomy for Stage I Renal Cell Carcinoma: A Propensity-Matched Cohort Study Focusing Upon Long-Term Follow-Up of Oncologic Outcomes https://lnkd.in/dPfTsF2C
To view or add a comment, sign in
-
-
Gain valuable insights into how collaboration among different healthcare professionals can lead to early detection and better outcomes for patients with advanced cases of basal cell carcinoma (BCC) and advanced cutaneous squamous cell carcinoma (CSCC). Register here: https://okt.to/jbM5hq
To view or add a comment, sign in
-
-
The #KIT ligand #KITLG promotes portal vein tumor #thrombosis by up-regulating COL4A1 through STAT3-SMAD2 signaling in hepatocellular carcinoma https://lnkd.in/egPH4d6Y
To view or add a comment, sign in
-
-
Overall survival rate estimated at 24 months was 52.4% with generally tolerated safety profile. At #ASCO24, Dr. David Cognetti presented the updated safety and efficacy findings from an interim evaluation of Rakuten Medical’s open-label Phase 1b/2 study of #photoimmunotherapy using ASP-1929 in combination with anti-PD-1 for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Based on these results, Rakuten Medical plans to initiate a new phase 3 clinical trial with a primary endpoint of OS in the second half of 2024. Learn more: https://lnkd.in/gBjPvGzi #Alluminox
To view or add a comment, sign in
-
-
First follow-up of neoadjuvant cemiplimab in SCC published last October 2023. 📍 This single arm, multicentre, phase 2 study demonstrated a high rate of pathological complete response (51%) among patients with resectable cutaneous squamous cell carcinoma who received neoadjuvant cemiplimab. 🤓 📍 Results from this follow-up analysis further support the safety and clinical activity of perioperative cemiplimab, with encouraging event-free survival in patients with any degree of pathologic response. 🤓 https://lnkd.in/g2PUuGfP #neoadjuvantimmunotherapy #skincancerdoctor #nonmelanomaskincancer #medicaloncologist
To view or add a comment, sign in
-
-
🔪🆚☢️ #Liver resection (LR) is better than radio frequency ablation (#RFA) for patients with <3 cm hepatocellular carcinoma (#HCC), new metaanalysis suggests. This is against the current recommendations, so this study opens the resection vs RFA debate again. (❗) Interestingly, the metaanalysis included trials with patients treated between 1981-2019. Since then, tumor biology could have changed (less #HCV related and more #MAFLD related HCC cases) and, more importantly, diagnostics, #surgery and RFA technique has could have improved a lot. More trials are required to research the topic.
Chirurgia Epatobiliopancreatica (HPB) e dei Trapianti di Fegato della Università degli Studi di Padova
Our new paper is out on BJS Open 🔥 Liver resection 🤜🤛 radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis 🆓 access here ▶️ https://lnkd.in/dSMxnS2B
To view or add a comment, sign in
-